Replies to post #82962 on Biotech Values

[genisi]

No idea either, suppose to be in pre-IND studies. CEPH intend to file IND on ALK inhibitor (CEP-28122) for solid tumors in Q3.

[tony111]

ARIA's alk inhibitor has good pharmokinetics so the QD schedule might have an edge over PFE's, but PFE's alk inhibitor might be more effective since it also inhibits cMet. Assume they have same efficacy and safety profile, ARIA's drug is behind PFE by more than 2 years. Is there known cases where a drug with equal efficacy but taken QD took over the market of a drug taken BID?